PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Jul 18, 2019 → Mar 1, 2026
NCT ID
NCT04006457About PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine is a phase 3 stage product being developed by Pfizer for Alopecia Areata. The current trial status is active. This product is registered under clinical trial identifier NCT04006457. Target conditions include Alopecia Areata.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006457 | Phase 3 | Active |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 65 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 77 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 2 | 52 |
| Daxdilimab | Amgen | Phase 2 | 51 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| LITFULO | Pfizer | Pre-clinical | 22 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 76 |